Robert W. Shafer

25.2k total citations · 6 hit papers
268 papers, 17.3k citations indexed

About

Robert W. Shafer is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Robert W. Shafer has authored 268 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Infectious Diseases, 207 papers in Virology and 38 papers in Epidemiology. Recurrent topics in Robert W. Shafer's work include HIV/AIDS drug development and treatment (216 papers), HIV Research and Treatment (207 papers) and HIV/AIDS Research and Interventions (138 papers). Robert W. Shafer is often cited by papers focused on HIV/AIDS drug development and treatment (216 papers), HIV Research and Treatment (207 papers) and HIV/AIDS Research and Interventions (138 papers). Robert W. Shafer collaborates with scholars based in United States, United Kingdom and Switzerland. Robert W. Shafer's co-authors include Soo‐Yon Rhee, Bryan Chan, Jonathan Schapiro, Mark A. Winters, David Katzenstein, Tommy F. Liu, Deenan Pillay, Michele W. Tang, Gregory K. Robbins and Roger Paredes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Robert W. Shafer

263 papers receiving 16.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database

1999 763 citations Robert W. Shafer et al. profile →
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

2009 731 citations Michael R. Jordan, Anne–Mieke Vandamme et al. PLoS ONE profile →
The biological and clinical significance of emerging SARS-CoV-2 variants

2021 626 citations Kaiming Tao, Philip L. Tzou et al. profile →
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation

2006 494 citations Robert W. Shafer et al. Clinical Infectious Diseases profile →
2015 update of the drug resistance mutations in HIV-1

2015 288 citations Vincent Cálvez, Victoria A. Johnson et al. PubMed profile →
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic

2023 71 citations Hector Bonilla, Mitchell G. Miglis et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert W. Shafer	14.1k	11.7k	3.5k	2.6k	1.2k	268	17.3k
Charles A. Boucher	9.7k 0.7×	9.1k 0.8×	4.2k 1.2×	1.5k 0.6×	1.6k 1.4×	345	17.4k
Daniel R. Kuritzkes	14.3k 1.0×	13.9k 1.2×	3.2k 0.9×	2.7k 1.0×	938 0.8×	370	19.9k
Carlo Federico Perno	8.0k 0.6×	6.9k 0.6×	3.5k 1.0×	2.5k 0.9×	1.4k 1.2×	558	13.4k
Huldrych F. Günthard	13.2k 0.9×	13.7k 1.2×	4.3k 1.2×	2.2k 0.8×	1.4k 1.2×	371	19.3k
Jean‐Michel Molina	11.4k 0.8×	7.2k 0.6×	5.9k 1.7×	1.1k 0.4×	1.3k 1.1×	547	18.7k
Robert W. Coombs	11.8k 0.8×	8.9k 0.8×	5.7k 1.6×	1.1k 0.4×	506 0.4×	235	16.8k
David Katzenstein	11.5k 0.8×	9.5k 0.8×	3.6k 1.0×	825 0.3×	676 0.6×	281	15.2k
Scott M. Hammer	12.3k 0.9×	10.2k 0.9×	3.9k 1.1×	864 0.3×	886 0.8×	129	16.0k
Andrea Antinori	9.9k 0.7×	7.4k 0.6×	4.1k 1.2×	1.2k 0.5×	786 0.7×	561	15.4k
John W. Mellors	18.2k 1.3×	19.1k 1.6×	4.5k 1.3×	2.7k 1.0×	850 0.7×	408	24.9k

Countries citing papers authored by Robert W. Shafer

Since Specialization

Citations

This map shows the geographic impact of Robert W. Shafer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Shafer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Shafer more than expected).

Fields of papers citing papers by Robert W. Shafer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Shafer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Shafer. The network helps show where Robert W. Shafer may publish in the future.

Co-authorship network of co-authors of Robert W. Shafer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Shafer. A scholar is included among the top collaborators of Robert W. Shafer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Shafer. Robert W. Shafer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tao, Kaiming, et al.. (2025). GenBank2PubMed: bridging viral genomic data and the scientific literature with AI-assisted curation. Scientific Reports. 15(1). 45009–45009.

Wensing, Annemarie M. J., Charlotte Charpentier, Vincent Cálvez, et al.. (2025). Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance. Clinical Infectious Diseases. 81(4). e132–e136. 6 indexed citations

Tao, Kaiming, et al.. (2024). Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments. Antiviral Research. 230. 105988–105988. 4 indexed citations

Chu, Carolyn, Kaiming Tao, Ava Avalos, et al.. (2024). Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Viruses. 16(3). 399–399. 23 indexed citations

Miglis, Mitchell G., Lü Tian, Hector Bonilla, et al.. (2024). Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported Data. Vaccines. 12(12). 1427–1427. 1 indexed citations

Nouhin, Janin, Philip L. Tzou, Soo‐Yon Rhee, et al.. (2023). Human immunodeficiency virus 1 5′-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations. Journal of General Virology. 104(10).

Rhee, Soo‐Yon, et al.. (2022). Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system. PLoS ONE. 17(2). e0263742–e0263742. 21 indexed citations

Saladini, Francesco, Adele Boccuto, Filippo Dragoni, et al.. (2020). In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. Journal of Antimicrobial Chemotherapy. 76(1). 130–134. 15 indexed citations

Tzou, Philip L., Soo‐Yon Rhee, & Robert W. Shafer. (2019). Amino Acid Prevalence of HIV-1 pol Mutations by Direct Polymerase Chain Reaction and Single Genome Sequencing. AIDS Research and Human Retroviruses. 35(10). 924–929. 2 indexed citations

10.

Rhee, Soo‐Yon, Kris Sankaran, Vici Varghese, et al.. (2016). HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. Journal of Virology. 90(13). 6058–6070. 68 indexed citations

11.

Wensing, Annemarie M. J., Vincent Cálvez, Huldrych F. Günthard, et al.. (2016). 2015 Update of the Drug Resistance Mutations in HIV-1.. PubMed. 23(4). 132–41. 56 indexed citations

12.

Wensing, Annemarie M. J., Vincent Cálvez, Huldrych F. Günthard, et al.. (2016). 2017 Update of the Drug Resistance Mutations in HIV-1.. PubMed. 24(4). 132–133. 149 indexed citations

13.

Feder, Alison F., Soo‐Yon Rhee, Susan Holmes, et al.. (2016). More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. eLife. 5. 48 indexed citations

14.

Varghese, Vici, et al.. (2016). Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Research and Human Retroviruses. 32(7). 702–704. 5 indexed citations

15.

Shafer, Robert W.. (2009). O desafio da resistência à medicação antirretroviral em crianças infectadas pelo HIV-1. Jornal de Pediatria. 85(2). 91–94. 1 indexed citations

16.

Mitsuya, Yumi, Vici Varghese, Chunlin Wang, et al.. (2008). Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations. Journal of Virology. 82(21). 10747–10755. 63 indexed citations

17.

Mitsuya, Yumi, Mark A. Winters, W. Jeffrey Fessel, et al.. (2006). N88D Facilitates the Co-occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV Type 1 Protease following Nelfinavir Treatment Failure. AIDS Research and Human Retroviruses. 22(12). 1300–1305. 19 indexed citations

18.

Vijver, David van de, Rob Schuurman, Christian Nielsen, et al.. (2003). A systematic approach that identifies 11 new mutations as indicators of transmission of resistance. Antiviral Therapy. 8(3). 2 indexed citations

19.

Schmidt, Bárbara, Klaus Korn, Wilco Keulen, et al.. (2002). Determination of the optimal cut-offs for predicting the phenotype of nine different HIV drug-resistance algorithms. Antiviral Therapy. 7. 1 indexed citations

20.

Eshleman, Susan H., Matthew J. Gonzales, Graziella Becker‐Pergola, et al.. (2002). Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and D. AIDS Research and Human Retroviruses. 18(7). 507–511. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact